A new co-operative group: the European Myeloma Network Trialist Group
DOI: 10.1080/10428190903191874
Publication date: October 2009
Publications
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Main author: Bringhen
DOI: 10.3324/haematol.2018.191288
Publication date: September 2018
European Myeloma Network guidelines for the management of multiple myeloma-related complications
Main author: Terpos
DOI: 10.3324/haematol.2014.117176
Publication date: January 2015
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Main author: Gavriatopoulou
DOI: 10.1038/s41375-018-0209-7
Publication date: September 2018
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Main author: Engelhardt
DOI: 10.3324/haematol.2013.099358
Publication date: January 2014
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Main author: Caers
DOI: 10.3324/haematol.2018.189159
Publication date: November 2018
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Main author: Engelhardt
DOI: 10.3109/10428194.2010.516378
Publication date: January 2010
European myeloma network: the value of collaborative research
Main author: Sonneveld
DOI: 10.1159/000087039
Publication date: January 2005
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Main author: Gay
DOI: 10.3324/haematol.2017.174573
Publication date: February 2018
Insights on Multiple Myeloma Treatment Strategies
Main author: Mateos
DOI: 10.1097/HS9.0000000000000163
Publication date: December 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.
Main author: Gay
DOI: 10.1001/jamaoncol.2018.2961
Publication date: October 2018
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Main author: Bringhen
DOI: 10.1038/s41375-018-0024-1
Publication date: January 2018
Connected Trials:
EMN07
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Main author: Dimopoulos
DOI: 10.1038/leu.2011.3.
Publication date: January 2011
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Main author: Larocca
DOI: 10.1038/s41375-018-0142-9
Publication date: January 2018
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Main author: Palumbo
DOI: 10.1182/blood-2011-06-358812
Publication date: January 2011
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Main author: Sonneveld
DOI: 10.1182/blood-2014-05-576256.
Publication date: January 2015
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
Main author: Ludwig
DOI: 10.1038/leu.2017.353
Publication date: January 2017
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Main author: Ludwig
DOI: 10.1038/s41375-018-0040-1
Publication date: January 2018
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Main author: Bringhen
DOI: 10.1111/joim.12882
Publication date: February 2019
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Main author: Dimopoulos
DOI: 10.1182/blood-2013-05-503862
Publication date: January 2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Main author: Dimopoulos
DOI: 10.1182/blood-2013-05-503862.
Publication date: January 2013
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Main author: Ross
DOI: 10.3324/haematol.2011.056176
Publication date: February 2012
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Main author: Rawstron
DOI: 10.3324/haematol.11080
Publication date: January 2008
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network
Main author: Ozaki
DOI: 10.1159/000357394
Publication date: January 2014
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Main author: Fayers
DOI: 10.1182/blood-2011-03-341669.
Publication date: January 2011
- 1
- 2